Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,443 across all filing types
Latest filing 2018-09-27 Annual Report
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Annual Report to shareholders 75 pages 4.2MB
Annual Report Classification · 100% confidence The document is titled 'Imugene Limited Annual report: 2018' and contains detailed sections typical of an annual report, including Chairman's letter, review of operations and activities, directors' report, auditor's independence declaration, corporate governance statement, and comprehensive financial statements such as consolidated statement of profit or loss, financial position, changes in equity, cash flows, notes to financial statements, directors' declaration, and independent auditor's report. The document covers the full fiscal year ended 30 June 2018 and includes detailed financial data, operational highlights, and strategic outlook. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is the full annual report rather than an announcement or summary. Therefore, the appropriate classification is Annual Report (10-K). FY 2018
2018-09-27 English
Appendix 4G 10 pages 155.2KB
Regulatory Filings
2018-09-27 English
Imugene commences cGMP manufacture of PD-1 cancer vaccine 2 pages 140.1KB
Capital/Financing Update Classification · 85% confidence The document is an ASX announcement from Imugene Limited dated 21 September 2018. It announces the commencement of cGMP manufacture of a clinical batch of a cancer vaccine (KEY-Vaxx) and the filing of a new patent. The content focuses on operational updates, manufacturing progress, and intellectual property filings. There are no financial statements, earnings data, or detailed financial analysis. The document is relatively short (4508 characters) and serves as a corporate update rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is an announcement about manufacturing and patent progress, which aligns best with Capital/Financing Update (CAP) as it relates to clinical manufacturing commencement and patent protection, which are key capital and development milestones for a clinical-stage company.
2018-09-20 English
Imugene appoints gastrointestinal cancer expert to SAB 2 pages 59.6KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement dated 18 September 2018 about the appointment of a new member to the Scientific Advisory Board of Imugene Limited. It focuses on management/board changes, specifically the addition of Professor Tanios Bekaii-Saab to the Scientific Advisory Board. There is no financial data, no report publication, no voting results, no legal proceedings, no capital changes, and no earnings information. The content clearly fits the category of Board/Management Information (MANG) as it announces a change in the company's advisory board composition.
2018-09-17 English
Imugene Completes Phase 1b Cancer Vaccine Trial Recruitment 4 pages 401.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Imugene Limited about the completion of recruitment for a Phase 1b clinical trial of a cancer vaccine. It provides detailed information about the trial design, endpoints, and future plans for Phase 2. The content is focused on clinical trial progress and company updates rather than financial results or regulatory filings. It is not a financial report, earnings release, or management discussion. The document is a corporate announcement about a clinical milestone, which fits best under the category of Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit into other specific categories like earnings, capital updates, or management changes.
2018-09-10 English
Appendix 4E and Audited Financial Report 63 pages 542.5KB
Annual Report Classification · 100% confidence The document is titled 'Imugene Limited Appendix 4E 30 June 2018' and contains detailed financial information for the year ended 30 June 2018, including audited financial statements, directors' report, auditor's independence declaration, corporate governance statement, and notes to the financial statements. It includes comprehensive financial data such as profit and loss, financial position, cash flows, and detailed operational and financial reviews. The document also references the audit report and includes the independent auditor's report. The length is substantial (15,000 characters) and contains the full annual financial report content rather than just an announcement or summary. Appendix 4E is an Australian regulatory filing that accompanies the annual report and contains the full audited financial report. Therefore, this document is best classified as an Annual Report (10-K equivalent). FY 2018
2018-08-30 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.